Close Menu

Agilent

For the three months ended July 31,the firm's revenues contracted to $1.26 billion from $1.27 billion in Q3 2019, beating Wall Street analysts' average estimate of $1.21 billion.

The firm said it plans to use the proceeds to support the launch of its first product based on its structures for lossless ion manipulation ion mobility system.

The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.

While there were a few new mass spectrometry instrument introductions, vendors focused primarily on software and sample separation advances.

The companies aim to develop robust methods for experiments analyzing thousands of tissue and plasma proteomes.

The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility. 

For the three months ended April 30, the firm's revenues were $1.24 billion, flat with $1.24 billion in Q2 2019 but beating Wall Street analysts' average estimate of $1.21 billion.

Agilent, which co-led Mission Bio's 2018 $30 million Series B financing round, will comarket the Tapestri platform to cancer researchers in North America.

The firm noted a disruption in global business in late March, as customers closed or restricted access to their facilities in an attempt to slow the spread of the coronavirus.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.